Phase

Phase specializes in 3D-printed microfluidics, offering a proprietary platform that allows for the printing of Polydimethylsiloxane (PDMS) and other biocompatible materials at high resolution and scale. This supports customizable microfluidic device production, integrating valves, sensors, and electrodes during the printing process. Phase’s in-house LE3D printing technology that enables users to design and fabricate microfluidic devices. These include multilayered, biomimicking devices with features such as embedded gels and electrodes.

Key customers and partnerships

In January 2022, Phase partnered with Virginia Tech to enable the university to use its LE3D printing technology to develop microfluidic devices for new medical treatments. The joint project was funded by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health.

Funding and financials

In February 2024, Phase received a grant of USD 1.8 million from the National Institutes of Health for a 3D printing project with Georgia Tech, Harvard Medical School's Massachusetts General Hospital, and Virginia Tech. The funding was earmarked to build on the work of its existing projects and create a blood-brain barrier device designed to overcome the limitations of current brain models. 

Key competitors: No comparable competitors. (There are no companies in coverage who targets biocompatible materials)